TCRX News & Events

TScan Therapeutics announced completion of enrollment into Cohort C of the ALLOHA study. Patients in Cohort C are being treated using the new commercial-ready manufacturing process. The Company also announced that the U.S. Food and Drug Administration, FDA, has cleared its investigational new drug, IND, applications for TSC-102-A01 and TSC-102-A03 for patients with HLA types A 01:01 and A 03:01, respectively.

TScan Therapeutics announced updated results from the ongoing ALLOHA Phase 1 trial of TSC-101 in patients with heme malignancies undergoing allogeneic hematopoietic cell transplantation, HCT. The data is being featured in a poster presentation at the 67th American Society of Hematology, ASH, Annual Meeting and Exposition. Key Presentation Highlights: Relapse-free survival and overall survival were improved in the treatment arm relative to the control arm; All 3 TSC-101-treated patients that reached two years of follow-up remained relapse-free as of the data cutoff, compared to 1 of 4 patients in the control arm, consistent with effective elimination of residual cancer cells post-HCT and durable remission with TSC-101 infusion; TSC-101 infusions were well-tolerated at all dose levels, with no dose-limiting toxicities. Observed adverse events were similar across the treatment and control arms and were generally consistent with post-HCT adverse events; Mixed chimerism or relapses following TSC-101 infusions were found to be significantly associated with greater ex vivo expansion of TCR-T cells during the manufacturing process

Reports Q3 revenue $2.511M, consensus $1.98M. "Following a productive meeting with the FDA, we now have a clearly defined pivotal trial design for TSC-101, and we also have an improved commercial-ready manufacturing process in place. We are focused on advancing this promising program for patients with AML and MDS and look forward to sharing updated results from the ALLOHA Phase 1 trial at ASH next month," said Gavin MacBeath, Ph.D., Chief Executive Officer. "After infusing the first two patients with multiplex TCR-T in our PLEXI-T trial, we have now paused further enrollment to focus on preclinical development of in vivo engineering to treat patients with solid tumors. We believe this approach represents a promising and more cost-efficient way to deliver off-the-shelf, multiplexed TCR-T cells."